Prosecution Insights
Last updated: April 19, 2026

Juniv LLP

16 pending office actions • 13 clients

Portfolio Summary

16
Total Pending OAs
3
Final Rejections
13
Non-Final OAs

Client Portfolio (13 clients)

Client (Assignee)Pending OAs
BIOTHERYX, INC. 4
Sichuan Real&Best Biotech Co., Ltd. 1
NucMito Pharmaceuticals Co., Ltd. 1
Suzhou Puhe BioPharma Co., Ltd. 1
Numaferm GmbH 1
Universitat Bielefeld 1
NucMito Pharmaceuticals Co., Ltd. 1
Eubulus Biotherapeutics Inc. 1
Crage Medical Co., Limited 1
NovoMedix, LLC 1
Cure Genetics Co., Limited 1
Ic-Medtech Corp. 1
Carsgen Life Sciences Co., Ltd. 1

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
18649917 ENGINEERED ALPHA-GALACTOSIDASE A (A-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE Sichuan Real&Best Biotech Co., Ltd. MOEHLMAN, ANDREW TERRY 1655 Non-Final OA Apr 29, 2024
18684902 ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. CHAO, ALLEN 1622 Non-Final OA Feb 20, 2024
18542629 KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. KUCKLA, ANNA GRACE 1626 Non-Final OA Dec 16, 2023
18505975 INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS NucMito Pharmaceuticals Co., Ltd. FOWLER, ALAN JEROME 1691 Non-Final OA Nov 09, 2023
18558522 PYRIMIDINYLAMINOBENZENES FOR LUNG CANCER TREATMENT Suzhou Puhe BioPharma Co., Ltd. HEES, OLIVER DRAGON 1628 Non-Final OA Nov 01, 2023
18550967 FUSION PROTEINS COMPRISING GG REPEAT SEQUENCES Numaferm GmbH MCKNIGHT, CIARA A 1656 Non-Final OA Sep 17, 2023
18547018 CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF Universitat Bielefeld BRAUN, MADELINE E 1624 Non-Final OA Aug 18, 2023
18256636 PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. MCDOWELL, BRIAN E 1624 Non-Final OA Jun 09, 2023
18256237 RXR-ALPHA BINDERS AND RXR-ALPHA/PLK1 MODULATORS NucMito Pharmaceuticals Co., Ltd. STEIN, LEAH ELIZABETH 1641 Non-Final OA Jun 07, 2023
18255855 HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS Eubulus Biotherapeutics Inc. SHOWALTER, ALEXANDER KEITH 1629 Non-Final OA Jun 02, 2023
18245125 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. WHITE, DAWANNA SHAR-DAY 1627 Final Rejection Mar 13, 2023
18174565 COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY Crage Medical Co., Limited BELYAVSKYI, MICHAIL A 1644 Non-Final OA Feb 24, 2023
17999843 BIARYLSULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING FIBROTIC LUNG DISEASE NovoMedix, LLC WELLS, LAUREN QUINLAN 1622 Final Rejection Nov 23, 2022
17634963 GENETICALLY ENGINEERED CELLS AND USES THEREOF Cure Genetics Co., Limited DIBRINO, MARIANNE 1641 Non-Final OA Nov 09, 2022
17806689 ASCORBIC ACID AND QUINONE COMPOUND FOR CANCER TREATMENT Ic-Medtech Corp. SIMMONS, CHRIS E 1622 Final Rejection Jun 13, 2022
17623481 CELL FOR RESISTING TRANSPLANT REACTION AND METHOD Carsgen Life Sciences Co., Ltd. TRAN, KHOA NHAT 1632 Non-Final OA Dec 28, 2021

Managing Juniv LLP's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month